LCE3C Inhibitors
LCE3C Inhibitors comprise a spectrum of chemical compounds that suppress the expression or functional activity of LCE3C, a protein involved in epidermal differentiation and repair processes. Calcipotriol and Retinoic Acid, both acting as modulators of gene transcription through their respective receptors, VDR and retinoid receptors, serve to reduce LCE3C levels, with Calcipotriol affecting LCE3C inducibility by calcium, and Retinoic Acid regulating keratinocyte proliferation. Similarly, immunosuppressive agents like Cyclosporin A and FK-506 work through inhibition of calcineurin to suppress T-cell activation, which can lead to a reduced expression of LCE3C. Hydrocortisone, leveraging its glucocorticoid receptor-mediated gene modulation, and Methotrexate, through its anti-inflammatory and antiproliferative actions, also contribute to the downregulation of LCE3C expression.
Tazarotene, being a synthetic retinoid, impacts LCE3C by influencing keratinocyte differentiation, while Anthralin's action on keratinocyte proliferation and differentiation may indirectly reduce LCE3C expression. Imiquimod's immunomodulatory effects, via Toll-like receptor 7 activation, lead to changes in the local cytokine environment, potentially decreasing LCE3C levels. L-NAME, by inhibiting nitric oxide synthase, reduces inflammation and consequently the expression of inflammation-associated LCE3C. Pimecrolimus, similar to FK-506, suppresses T-cell-mediated cytokine production, thus diminishing LCE3C expression. Finally, the keratolytic action of Salicylic Acid, coupled with its anti-inflammatory properties, can lead to a reduction in LCE3C expression by altering the function of keratinocytes and reducing skin inflammation. Collectively, these LCE3C Inhibitors exert their effects through a diverse array of biochemical pathways that ultimately converge on the downregulation of LCE3C, highlighting their potential role in modulating processes related to skin homeostasis and pathology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Calcipotriol | 112965-21-6 | sc-203537 sc-203537A | 10 mg 50 mg | $203.00 $832.00 | 4 | |
A vitamin D analog that binds to the vitamin D receptor (VDR) and modulates gene expression. By influencing VDR signaling, Calcipotriol can diminish the expression of LCE3C, which is inducible by calcium and involved in epidermal differentiation. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
An active metabolite of vitamin A that regulates gene expression through retinoid receptors. Retinoic acid can downregulate LCE3C as part of the modulation of keratinocyte differentiation and proliferation. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Binds to cyclophilins and inhibits calcineurin, thus preventing the activation of T cells. By inhibiting T-cell-derived cytokines, Cyclosporin A indirectly diminishes LCE3C expression, which can be upregulated by inflammatory signals. | ||||||
Hydrocortisone | 50-23-7 | sc-300810 | 5 g | $102.00 | 6 | |
A glucocorticoid that binds to the glucocorticoid receptor and modulates gene transcription. Hydrocortisone can decrease the expression of LCE3C by affecting pathways involved in skin inflammation and repair. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
A dihydrofolate reductase inhibitor that has anti-inflammatory effects. Methotrexate can lead to a reduction in LCE3C expression as it diminishes the proliferation of keratinocytes and modulates immune responses in the skin. | ||||||
Tazarotene | 118292-40-3 | sc-220193 | 10 mg | $103.00 | ||
Binds to retinoic acid receptors, altering gene expression and potentially reducing LCE3C expression as part of the normalization of keratinocyte differentiation. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
Inhibits calcineurin, leading to decreased T-cell activation. FK-506, thereby, can lower the expression of LCE3C, which is responsive to immune signaling in the skin. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
An immune response modifier that activates immune cells via Toll-like receptor 7. By altering the cytokine milieu in the skin, Imiquimod can decrease LCE3C expression indirectly through its immunomodulatory effects. | ||||||
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $48.00 $107.00 $328.00 | 45 | |
Inhibits nitric oxide synthase, reducing nitric oxide production. Decreased nitric oxide can lead to reduced inflammation and thus indirectly diminish the expression of LCE3C, which is associated with inflammatory skin conditions. | ||||||
Pimecrolimus | 137071-32-0 | sc-208172 | 1 mg | $140.00 | 2 | |
An ascomycin macrolactam derivative with immunomodulating properties similar to tacrolimus. Pimecrolimus can inhibit T cell activation and subsequent cytokine release, consequently diminishing the expression of LCE3C. | ||||||